Annual CFO
-$12.85 M
+$121.00 K+0.93%
01 December 2023
Summary:
Plus Therapeutics annual cash flow from operations is currently -$12.85 million, with the most recent change of +$121.00 thousand (+0.93%) on 01 December 2023. During the last 3 years, it has fallen by -$4.42 million (-52.37%). PSTV annual CFO is now -1067.21% below its all-time high of -$1.10 million, reached on 31 December 2005.PSTV Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$3.68 M
-$2.53 M-220.00%
01 September 2024
Summary:
Plus Therapeutics quarterly cash flow from operations is currently -$3.68 million, with the most recent change of -$2.53 million (-220.00%) on 01 September 2024. Over the past year, it has dropped by -$1.80 million (-95.64%). PSTV quarterly CFO is now -183.77% below its all-time high of $4.39 million, reached on 31 December 2005.PSTV Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$11.22 M
-$1.28 M-12.88%
01 September 2024
Summary:
Plus Therapeutics TTM cash flow from operations is currently -$11.22 million, with the most recent change of -$1.28 million (-12.88%) on 01 September 2024. Over the past year, it has increased by +$1.63 million (+12.66%). PSTV TTM CFO is now -270.37% below its all-time high of $6.59 million, reached on 31 March 2006.PSTV TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTV Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -95.6% | +12.7% |
| 3 y3 years | -52.4% | -63.5% | -3.2% |
| 5 y5 years | -7.3% | -45.9% | -19.0% |
PSTV Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -52.4% | +0.9% | -220.0% | +36.5% | -12.9% | +25.3% |
| 5 y | 5 years | -117.6% | +0.9% | -455.2% | +36.5% | -171.2% | +25.3% |
| alltime | all time | -1067.2% | +63.6% | -183.8% | +65.2% | -270.4% | +68.5% |
Plus Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.68 M(+220.0%) | -$11.22 M(+12.9%) |
| June 2024 | - | -$1.15 M(-74.5%) | -$9.94 M(-14.1%) |
| Mar 2024 | - | -$4.51 M(+139.9%) | -$11.57 M(-10.0%) |
| Dec 2023 | -$12.85 M(-0.9%) | -$1.88 M(-21.6%) | -$12.85 M(-2.7%) |
| Sept 2023 | - | -$2.40 M(-13.6%) | -$13.20 M(-12.1%) |
| June 2023 | - | -$2.78 M(-52.0%) | -$15.03 M(+0.9%) |
| Mar 2023 | - | -$5.79 M(+159.3%) | -$14.89 M(+14.8%) |
| Dec 2022 | -$12.97 M(+26.2%) | -$2.23 M(-47.1%) | -$12.97 M(-2.9%) |
| Sept 2022 | - | -$4.22 M(+59.9%) | -$13.36 M(+17.3%) |
| June 2022 | - | -$2.64 M(-31.9%) | -$11.39 M(+2.2%) |
| Mar 2022 | - | -$3.88 M(+47.7%) | -$11.15 M(+8.5%) |
| Dec 2021 | -$10.28 M(+21.9%) | -$2.62 M(+16.6%) | -$10.28 M(-5.5%) |
| Sept 2021 | - | -$2.25 M(-6.2%) | -$10.88 M(-0.4%) |
| June 2021 | - | -$2.40 M(-20.2%) | -$10.93 M(+10.0%) |
| Mar 2021 | - | -$3.01 M(-6.8%) | -$9.94 M(+17.8%) |
| Dec 2020 | -$8.43 M(+42.8%) | -$3.22 M(+40.2%) | -$8.43 M(+102.1%) |
| Sept 2020 | - | -$2.30 M(+63.2%) | -$4.17 M(-5.1%) |
| June 2020 | - | -$1.41 M(-6.2%) | -$4.40 M(+6.3%) |
| Mar 2020 | - | -$1.50 M(-245.0%) | -$4.14 M(-29.9%) |
| Dec 2019 | -$5.91 M(-50.7%) | $1.04 M(-141.1%) | -$5.91 M(-37.4%) |
| Sept 2019 | - | -$2.52 M(+119.3%) | -$9.43 M(-1.3%) |
| June 2019 | - | -$1.15 M(-64.8%) | -$9.55 M(-14.1%) |
| Mar 2019 | - | -$3.27 M(+31.4%) | -$11.13 M(-7.1%) |
| Dec 2018 | -$11.97 M(-33.9%) | -$2.49 M(-6.0%) | -$11.97 M(-12.7%) |
| Sept 2018 | - | -$2.65 M(-2.7%) | -$13.71 M(-9.3%) |
| June 2018 | - | -$2.72 M(-33.9%) | -$15.11 M(-13.2%) |
| Mar 2018 | - | -$4.12 M(-2.5%) | -$17.42 M(-3.9%) |
| Dec 2017 | -$18.13 M(-7.2%) | -$4.22 M(+4.3%) | -$18.13 M(+0.3%) |
| Sept 2017 | - | -$4.05 M(-19.5%) | -$18.07 M(-3.2%) |
| June 2017 | - | -$5.03 M(+4.2%) | -$18.65 M(-3.4%) |
| Mar 2017 | - | -$4.83 M(+16.0%) | -$19.30 M(-1.2%) |
| Dec 2016 | -$19.53 M(-4.6%) | -$4.16 M(-10.3%) | -$19.53 M(-1.8%) |
| Sept 2016 | - | -$4.64 M(-18.3%) | -$19.89 M(-7.1%) |
| June 2016 | - | -$5.68 M(+12.2%) | -$21.41 M(+4.5%) |
| Mar 2016 | - | -$5.06 M(+11.9%) | -$20.50 M(+0.1%) |
| Dec 2015 | -$20.47 M(-32.5%) | -$4.52 M(-26.6%) | -$20.47 M(-2.1%) |
| Sept 2015 | - | -$6.16 M(+29.4%) | -$20.90 M(-4.9%) |
| June 2015 | - | -$4.76 M(-5.4%) | -$21.98 M(-16.7%) |
| Mar 2015 | - | -$5.03 M(+1.5%) | -$26.40 M(-13.0%) |
| Dec 2014 | -$30.33 M(-12.2%) | -$4.96 M(-31.5%) | -$30.33 M(-13.0%) |
| Sept 2014 | - | -$7.24 M(-21.1%) | -$34.87 M(-2.3%) |
| June 2014 | - | -$9.18 M(+2.4%) | -$35.69 M(+4.3%) |
| Mar 2014 | - | -$8.96 M(-5.7%) | -$34.23 M(-1.0%) |
| Dec 2013 | -$34.56 M(+7.4%) | -$9.50 M(+18.0%) | -$34.56 M(+3.5%) |
| Sept 2013 | - | -$8.05 M(+4.3%) | -$33.38 M(+0.4%) |
| June 2013 | - | -$7.72 M(-16.9%) | -$33.25 M(-1.6%) |
| Mar 2013 | - | -$9.29 M(+11.8%) | -$33.77 M(+4.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$32.19 M(-8.9%) | -$8.32 M(+5.0%) | -$32.19 M(+1.3%) |
| Sept 2012 | - | -$7.92 M(-3.9%) | -$31.78 M(+0.1%) |
| June 2012 | - | -$8.24 M(+6.9%) | -$31.75 M(-2.2%) |
| Mar 2012 | - | -$7.71 M(-2.3%) | -$32.47 M(-8.1%) |
| Dec 2011 | -$35.32 M(+49.8%) | -$7.90 M(+0.1%) | -$35.32 M(+9.7%) |
| Sept 2011 | - | -$7.89 M(-12.0%) | -$32.19 M(+3.2%) |
| June 2011 | - | -$8.97 M(-15.1%) | -$31.20 M(+16.7%) |
| Mar 2011 | - | -$10.56 M(+121.5%) | -$26.73 M(+13.4%) |
| Dec 2010 | -$23.57 M(-1.0%) | -$4.77 M(-30.9%) | -$23.57 M(-5.4%) |
| Sept 2010 | - | -$6.90 M(+53.5%) | -$24.93 M(+5.4%) |
| June 2010 | - | -$4.50 M(-39.3%) | -$23.66 M(-5.9%) |
| Mar 2010 | - | -$7.40 M(+20.8%) | -$25.14 M(+5.6%) |
| Dec 2009 | -$23.81 M(-28.7%) | -$6.13 M(+8.9%) | -$23.81 M(-4.8%) |
| Sept 2009 | - | -$5.63 M(-5.9%) | -$25.00 M(-8.3%) |
| June 2009 | - | -$5.98 M(-1.6%) | -$27.26 M(-10.0%) |
| Mar 2009 | - | -$6.07 M(-17.1%) | -$30.30 M(-9.2%) |
| Dec 2008 | -$33.39 M(+11.3%) | -$7.32 M(-7.1%) | -$33.39 M(-0.1%) |
| Sept 2008 | - | -$7.88 M(-12.6%) | -$33.42 M(+0.8%) |
| June 2008 | - | -$9.02 M(-1.5%) | -$33.17 M(+7.0%) |
| Mar 2008 | - | -$9.16 M(+24.5%) | -$31.00 M(+3.3%) |
| Dec 2007 | -$30.00 M(+82.0%) | -$7.36 M(-3.5%) | -$30.00 M(+8.5%) |
| Sept 2007 | - | -$7.63 M(+11.4%) | -$27.65 M(+3.2%) |
| June 2007 | - | -$6.85 M(-16.1%) | -$26.79 M(-2.6%) |
| Mar 2007 | - | -$8.16 M(+62.8%) | -$27.51 M(+66.9%) |
| Dec 2006 | -$16.48 M(+1397.1%) | -$5.01 M(-26.0%) | -$16.48 M(+132.9%) |
| Sept 2006 | - | -$6.77 M(-10.5%) | -$7.08 M(+41.4%) |
| June 2006 | - | -$7.57 M(-364.1%) | -$5.01 M(-176.0%) |
| Mar 2006 | - | $2.86 M(-34.8%) | $6.59 M(-698.4%) |
| Dec 2005 | -$1.10 M(-91.2%) | $4.39 M(-193.5%) | -$1.10 M(-87.3%) |
| Sept 2005 | - | -$4.70 M(-216.6%) | -$8.68 M(+35.9%) |
| June 2005 | - | $4.03 M(-183.5%) | -$6.38 M(-55.0%) |
| Mar 2005 | - | -$4.83 M(+51.4%) | -$14.19 M(+12.9%) |
| Dec 2004 | -$12.57 M(+73.6%) | -$3.19 M(+32.5%) | -$12.57 M(+29.1%) |
| Sept 2004 | - | -$2.40 M(-36.4%) | -$9.74 M(+5.1%) |
| June 2004 | - | -$3.78 M(+17.9%) | -$9.27 M(+39.6%) |
| Mar 2004 | - | -$3.21 M(+805.4%) | -$6.64 M(-8.3%) |
| Dec 2003 | -$7.25 M(+5.2%) | -$354.00 K(-81.7%) | -$7.25 M(-18.8%) |
| Sept 2003 | - | -$1.93 M(+67.9%) | -$8.92 M(+21.5%) |
| June 2003 | - | -$1.15 M(-69.8%) | -$7.34 M(-15.3%) |
| Mar 2003 | - | -$3.81 M(+88.0%) | -$8.66 M(+25.8%) |
| Dec 2002 | -$6.89 M(-17.3%) | -$2.03 M(+475.6%) | -$6.89 M(+41.7%) |
| Sept 2002 | - | -$352.00 K(-85.8%) | -$4.86 M(+7.8%) |
| June 2002 | - | -$2.48 M(+22.1%) | -$4.51 M(+122.1%) |
| Mar 2002 | - | -$2.03 M | -$2.03 M |
| Dec 2001 | -$8.32 M(+179.1%) | - | - |
| Dec 2000 | -$2.98 M(-41.6%) | - | - |
| Dec 1999 | -$5.11 M(+235.3%) | - | - |
| Dec 1998 | -$1.52 M | - | - |
FAQ
- What is Plus Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Plus Therapeutics?
- What is Plus Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Plus Therapeutics?
- What is Plus Therapeutics quarterly CFO year-on-year change?
- What is Plus Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Plus Therapeutics?
- What is Plus Therapeutics TTM CFO year-on-year change?
What is Plus Therapeutics annual cash flow from operations?
The current annual CFO of PSTV is -$12.85 M
What is the all time high annual CFO for Plus Therapeutics?
Plus Therapeutics all-time high annual cash flow from operations is -$1.10 M
What is Plus Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PSTV is -$3.68 M
What is the all time high quarterly CFO for Plus Therapeutics?
Plus Therapeutics all-time high quarterly cash flow from operations is $4.39 M
What is Plus Therapeutics quarterly CFO year-on-year change?
Over the past year, PSTV quarterly cash flow from operations has changed by -$1.80 M (-95.64%)
What is Plus Therapeutics TTM cash flow from operations?
The current TTM CFO of PSTV is -$11.22 M
What is the all time high TTM CFO for Plus Therapeutics?
Plus Therapeutics all-time high TTM cash flow from operations is $6.59 M
What is Plus Therapeutics TTM CFO year-on-year change?
Over the past year, PSTV TTM cash flow from operations has changed by +$1.63 M (+12.66%)